			Home About us Contact

PPI Use (ppi + use)

Distribution by Scientific Domains

Medical Sciences	100%

Selected Abstracts

Uses of proton pump inhibitors and serum potassium levels,

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 9 2009
Jen-Tzer Gau MD
Abstract Purpose Proton pump inhibitor (PPI) may suppress adrenal cortical steroid synthesis and release, thereby leading to electrolyte disturbances. Both hyponatremia and hyperkalemia in the setting of PPI therapy have been documented in case reports. The objective of this study was to examine the association between serum potassium (K+) level and PPI use. Methods A retrospective data analysis of hospitalized adults aged ,65 years during 2006, including PPI users (N,=,257) and PPI non-users (N,=,388), was conducted. Multiple linear and logistic regression analyses were used to assess the association between PPI use and serum K+ level. Results PPI users [mean age (SD):79.7 (8.0) years; 70% female] had significantly higher serum K+ levels than PPI non-users [80.2 (8.8) years; 64% female] on admission [4.13 (0.62) vs. 3.97 (0.57) mmol/L; p,<,0.001]. The linear regression model revealed that ,2 defined daily dose (DDD) units of PPI use were a significantly positive contributor to serum K+ levels (p,=,0.021) after adjusting for age, serum creatinine levels, sex, history of diabetes, and uses of the following drugs: angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker, , blocker, diuretics, spironolactone, K+ supplement, non-steroidal anti-inflammatory drugs, atypical antipsychotics, and narcotics. However, multiple logistic regression model revealed that high dose PPI therapy was not associated with an increased risk for hyperkalemia occurrence (p,=,0.762). Conclusion Higher serum K+ levels were observed among PPI users when compared to PPI non-users. High daily dose PPI therapy may be an independent positive predictor of serum potassium levels. Copyright © 2009 John Wiley & Sons, Ltd. [source]

Colorectal cancer risk in relation to use of acid suppressive medications,

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Issue 7 2009
Jessica Chubak PhD, MBHL
Abstract Purpose Acid suppressants are commonly prescribed medications. Laboratory studies suggest a mechanism by which they could increase colorectal cancer (CRC) risk. A few epidemiologic studies have investigated acid suppressant use and CRC risk; none has documented an overall association. We sought to investigate whether acid suppressants are associated with CRC risk. Methods We conducted a case,control study among members of an integrated healthcare delivery system in Washington State. Cases (N,=,641) were diagnosed with CRC between 2000 and 2003; controls (N,=,641) were randomly selected from enrollees and matched to cases on age, sex, and length of enrollment. We used conditional logistic regression to estimate the odds ratios (ORs) and 95% confidence intervals (CI) for CRC associated with the use of any acid suppressive medication, proton pump inhibitors (PPIs) only, histamine receptor antagonists (H2 blockers) only, or both PPIs and H2 blockers in relation to the use of neither PPIs nor H2 blockers. Results Use of PPIs exclusively was modestly associated with an increased risk of CRC, however this finding was consistent with chance and based on a small number of patients exposed (OR,=,1.7; 95%CI,=,0.8, 4.0). H2 blocker use alone was not related to CRC risk (OR,=,0.8; 95%CI,=,0.6, 1.1). Conclusions PPI use may be modestly associated with CRC risk; further research should be conducted in populations with long-term PPI use. Copyright © 2009 John Wiley & Sons, Ltd. [source]

Hoarseness: Is It Really Laryngopharyngeal Reflux?,

THE LARYNGOSCOPE, Issue 2 2008
Seth M. Cohen MD
Abstract Objective/Hypothesis: This study will test the hypothesis that proton pump inhibitor (PPI) use is prevalent among patients referred for hoarseness and will assess the ultimate diagnosis and factors associated with patients' voice outcomes. Study Design: Retrospective review of patients in a tertiary care voice clinic. Methods: Patients with a primary diagnosis of hoarseness, who were taking or had taken PPIs in the previous 2 months and referred to a tertiary care voice clinic, were identified. The dosage and length of PPI administration, patient report of gastroesophageal reflux (GER), presence of findings suggesting muscle tension dysphonia (MTD), patient demographics, diagnosis, chronicity of symptoms, interventions, follow-up, and outcome were determined. Results: Of 299 patients, 264 met the inclusion criteria. The mean age was 47.2 years, with a range of 18 to 89 years, with 26.7% male and 73.3% female. Among patients referred for voice problems, 148 (56.1%) had previously tried PPIs or were currently on PPI treatment; 44 (29.7%) stopped taking their PPI because of continued hoarseness, and 104 (70.3%) had persistent hoarseness and associated throat complaints despite continued PPI treatment. Among patients who quit taking their PPI because of continued voice complaints, 79.5% did not have traditional GER symptoms of heartburn or regurgitation. The most common treatment after referral was voice therapy, with an overall voice therapy response rate of 62.7%. Conclusions: PPI use is prevalent among patients referred because of persistent hoarseness. Whether patients have GER or MTD may influence patients' voice outcomes in response to PPI treatment. [source]